Io­n­is, Cy­cle­ri­on tout pos­i­tive da­ta read­outs; MA­IA prices first biotech IPO in over two months

Io­n­is put out pos­i­tive topline re­sults from a Phase IIb tri­al on end-stage re­nal dis­ease, in­ves­ti­gat­ing pa­tients on dial­y­sis.

The drug can­di­date, fe­s­om­ersen,

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER